A team of scientists from Proteon Pharmaceuticals, the Biobank Lodz, and the University of Agriculture in Cracow has developed an innovative method for identifying strains of Avian Pathogenic Escherichia coli (APEC). The findings of the latest research, published on March 17, 2025, in the open-access scientific magazine BMC Microbiology, open new possibilities for diagnostics and poultry health.
The publication, titled “A rapid detection of Avian Pathogenic Escherichia coli (APEC) strains based on a minimal number of virulence markers identified by whole genome sequencing,” presents a new approach that can significantly strengthen biosecurity measures and improve safety in poultry farming.
The outcomes were published in the article available here.
Highlights from the article:
- Colibacillosis, caused by Avian Pathogenic E. coli (APEC), is a major concern in poultry farming, leading to high mortality rates and economic losses. Effective detection of pathogenic strains is crucial for disease prevention and management.
- The study leveraged Whole Genome Sequencing (WGS) to identify key genetic markers that distinguish APEC from non-pathogenic strains.
- Researchers developed a rapid and cost-effective PCR test targeting three key virulence markers: iroC, hlyF, and wzx (O78 serotype), enabling precise detection of pathogenic strains.
- The test was thoroughly validated using in silico analysis and in ovo tests, confirming its high accuracy in identifying APEC strains.
- This multiplex PCR test provides a reliable, fast, and affordable method for diagnosing colibacillosis in poultry, supporting targeted interventions and reducing reliance on broad-spectrum antibiotics.
At Proteon Pharmaceuticals, we develop science-driven solutions that support animal health, help prevent diseases, and contribute to greater food safety worldwide.
Researchers & authors: J. Kazimierczak (Proteon Pharmaceuticals), K. Pospiech (Proteon Pharmaceuticals), P. Sowińska (Proteon Pharmaceuticals), A. Pękala (Proteon Pharmaceuticals), P. Borówka, Ewelina A. Wójcik (Proteon Pharmaceuticals), B. Marciniak, M. W. Lis, D. Strapagiel & J. Dastych (Proteon Pharmaceuticals)
